This is definitely an odd one and I have not followed the Company at all. However, on the face of it this appears to read very well. Biotechs a minefield and often a binary outcome, so no surprise to see cynical posts. But I have taken a small punt because it has potential to take on a drug that appears roundly despised that's making a lot of revenue. And the mkt cap for a potential game changer is ludicrous.
Ann: Zeliras diabetic nerve pain drug outperforms Lyrica, page-46
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
